PharmaCyte Biotech Net Income
| PMCB Stock | USD 0.74 0 0.16% |
As of the 9th of February, PharmaCyte Biotech holds the Semi Deviation of 5.45, coefficient of variation of 22322.05, and Risk Adjusted Performance of 0.0128. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of PharmaCyte Biotech, as well as the relationship between them.
PharmaCyte Biotech Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Income | 35.3 M | 37 M | |
| Net Income From Continuing Ops | 35.3 M | 37 M | |
| Net Loss | -4.9 M | -5.1 M | |
| Net Income Per Share | 3.76 | 3.95 | |
| Net Income Per E B T | 1.15 | 1.30 |
PharmaCyte | Net Income | Build AI portfolio with PharmaCyte Stock |
Analyzing PharmaCyte Biotech's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing PharmaCyte Biotech's current valuation and future prospects.
Latest PharmaCyte Biotech's Net Income Growth Pattern
Below is the plot of the Net Income of PharmaCyte Biotech over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in PharmaCyte Biotech financial statement analysis. It represents the amount of money remaining after all of PharmaCyte Biotech operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is PharmaCyte Biotech's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PharmaCyte Biotech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 30.66 M | 10 Years Trend |
|
Net Income |
| Timeline |
PharmaCyte Net Income Regression Statistics
| Arithmetic Mean | 1,428,563 | |
| Coefficient Of Variation | 1,183 | |
| Mean Deviation | 11,604,941 | |
| Median | (3,827,341) | |
| Standard Deviation | 16,898,042 | |
| Sample Variance | 285.5T | |
| Range | 64.3M | |
| R-Value | 0.68 | |
| Mean Square Error | 165T | |
| R-Squared | 0.46 | |
| Significance | 0 | |
| Slope | 2,265,501 | |
| Total Sum of Squares | 4568.7T |
PharmaCyte Net Income History
Other Fundumenentals of PharmaCyte Biotech
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
PharmaCyte Biotech Net Income component correlations
PharmaCyte Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for PharmaCyte Biotech is extremely important. It helps to project a fair market value of PharmaCyte Stock properly, considering its historical fundamentals such as Net Income. Since PharmaCyte Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PharmaCyte Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PharmaCyte Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. Anticipated expansion of PharmaCyte directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive PharmaCyte Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding PharmaCyte Biotech requires distinguishing between market price and book value, where the latter reflects PharmaCyte's accounting equity. The concept of intrinsic value - what PharmaCyte Biotech's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push PharmaCyte Biotech's price substantially above or below its fundamental value.
It's important to distinguish between PharmaCyte Biotech's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PharmaCyte Biotech should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, PharmaCyte Biotech's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
PharmaCyte Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to PharmaCyte Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of PharmaCyte Biotech.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in PharmaCyte Biotech on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding PharmaCyte Biotech or generate 0.0% return on investment in PharmaCyte Biotech over 90 days. PharmaCyte Biotech is related to or competes with Quoin Pharmaceuticals, NovaBay Pharmaceuticals, Alaunos Therapeutics, VivoSim Labs, Impact BioMedical, Pasithea Therapeutics, and Polyrizon. PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for canc... More
PharmaCyte Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure PharmaCyte Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess PharmaCyte Biotech upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.43 | |||
| Information Ratio | (0) | |||
| Maximum Drawdown | 68.81 | |||
| Value At Risk | (8.33) | |||
| Potential Upside | 7.79 |
PharmaCyte Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for PharmaCyte Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as PharmaCyte Biotech's standard deviation. In reality, there are many statistical measures that can use PharmaCyte Biotech historical prices to predict the future PharmaCyte Biotech's volatility.| Risk Adjusted Performance | 0.0128 | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.91) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0121 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of PharmaCyte Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
PharmaCyte Biotech February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0128 | |||
| Market Risk Adjusted Performance | 0.0221 | |||
| Mean Deviation | 5.03 | |||
| Semi Deviation | 5.45 | |||
| Downside Deviation | 6.43 | |||
| Coefficient Of Variation | 22322.05 | |||
| Standard Deviation | 9.55 | |||
| Variance | 91.12 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.91) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0121 | |||
| Maximum Drawdown | 68.81 | |||
| Value At Risk | (8.33) | |||
| Potential Upside | 7.79 | |||
| Downside Variance | 41.4 | |||
| Semi Variance | 29.68 | |||
| Expected Short fall | (6.42) | |||
| Skewness | 3.83 | |||
| Kurtosis | 19.56 |
PharmaCyte Biotech Backtested Returns
At this point, PharmaCyte Biotech is out of control. PharmaCyte Biotech maintains Sharpe Ratio (i.e., Efficiency) of 0.0117, which implies the firm had a 0.0117 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for PharmaCyte Biotech, which you can use to evaluate the volatility of the company. Please check PharmaCyte Biotech's Coefficient Of Variation of 22322.05, semi deviation of 5.45, and Risk Adjusted Performance of 0.0128 to confirm if the risk estimate we provide is consistent with the expected return of 0.12%. The company holds a Beta of 2.71, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, PharmaCyte Biotech will likely underperform. PharmaCyte Biotech right now holds a risk of 9.81%. Please check PharmaCyte Biotech treynor ratio, expected short fall, and the relationship between the jensen alpha and potential upside , to decide if PharmaCyte Biotech will be following its historical price patterns.
Auto-correlation | 0.36 |
Below average predictability
PharmaCyte Biotech has below average predictability. Overlapping area represents the amount of predictability between PharmaCyte Biotech time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of PharmaCyte Biotech price movement. The serial correlation of 0.36 indicates that just about 36.0% of current PharmaCyte Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.36 | |
| Spearman Rank Test | 0.06 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
PharmaCyte Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, PharmaCyte Biotech reported net income of 30.66 M. This is 91.02% lower than that of the Biotechnology sector and 56.23% lower than that of the Health Care industry. The net income for all United States stocks is 94.63% higher than that of the company.
PharmaCyte Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PharmaCyte Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PharmaCyte Biotech could also be used in its relative valuation, which is a method of valuing PharmaCyte Biotech by comparing valuation metrics of similar companies.PharmaCyte Biotech is currently under evaluation in net income category among its peers.
PharmaCyte Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in PharmaCyte Biotech that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of PharmaCyte Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing PharmaCyte Biotech's value.| Shares | Advisor Group Holdings, Inc. | 2025-06-30 | 305 | Covestor Ltd | 2025-06-30 | 275 | Park Square Financial Group, Llc | 2025-06-30 | 37.0 | Sachetta Llc | 2025-06-30 | 14.0 | Bfsg, Llc | 2025-06-30 | 5.0 | Goss Wealth Management Llc | 2025-06-30 | 2.0 | Koesten Hirschmann & Crabtree Inc | 2025-06-30 | 2.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.0 | Ifp Advisors, Llc | 2025-06-30 | 1.0 | Vanguard Group Inc | 2025-06-30 | 194.4 K | Geode Capital Management, Llc | 2025-06-30 | 126.6 K |
PharmaCyte Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0476 | ||||
| Current Valuation | (7.19 M) | ||||
| Shares Outstanding | 10.13 M | ||||
| Shares Owned By Insiders | 8.56 % | ||||
| Shares Owned By Institutions | 4.29 % | ||||
| Number Of Shares Shorted | 177.32 K | ||||
| Price To Earning | 9.57 X | ||||
| Price To Book | 0.21 X | ||||
| EBITDA | 30.66 M | ||||
| Net Income | 30.66 M | ||||
| Cash And Equivalents | 82.23 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 3.28 M | ||||
| Current Ratio | 75.51 X | ||||
| Book Value Per Share | 5.25 X | ||||
| Cash Flow From Operations | (2.98 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (1.11) X | ||||
| Beta | 0.31 | ||||
| Market Capitalization | 7.51 M | ||||
| Total Asset | 55.17 M | ||||
| Retained Earnings | (84.97 M) | ||||
| Working Capital | 19.46 M | ||||
| Current Asset | 1.6 M | ||||
| Current Liabilities | 449 K | ||||
| Net Asset | 55.17 M |
About PharmaCyte Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PharmaCyte Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PharmaCyte Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PharmaCyte Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PharmaCyte Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PharmaCyte Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacyte Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacyte Biotech Stock:Check out For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. Anticipated expansion of PharmaCyte directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive PharmaCyte Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding PharmaCyte Biotech requires distinguishing between market price and book value, where the latter reflects PharmaCyte's accounting equity. The concept of intrinsic value - what PharmaCyte Biotech's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push PharmaCyte Biotech's price substantially above or below its fundamental value.
It's important to distinguish between PharmaCyte Biotech's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PharmaCyte Biotech should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, PharmaCyte Biotech's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.